IOBT - IO Biotech, Inc.

0.048
0.016   32.708%

Share volume: 481,589,630
Last Updated: 04-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.12%

PREVIOUS CLOSE
CHG
CHG%
$0.03
0.02
0.49%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
38%
Profitability 35%
Dept financing 33%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
-72.16%
3 Months
-84.82%
6 Months
-94.51%
1 Year
-94.92%
2 Year
-96.78%
Key data
Stock price
$0.05
P/E Ratio 
0.00
DAY RANGE
$0.03 - $0.06
EPS 
-$1.14
52 WEEK RANGE
$0.03 - $2.79
52 WEEK CHANGE
-$95.05
MARKET CAP 
23.921 M
YIELD 
N/A
SHARES OUTSTANDING 
71.949 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
1.69
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
$125,508,972
Company detail
CEO: Mai-Britt Zocca
Region: US
Website: iobiotech.com
Employees: 30
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1)

Recent news